Ensysce Biosciences (ENSC) Payables (2017 - 2025)

Ensysce Biosciences (ENSC) has reported Payables for 9 consecutive years, with $3.6 million the latest figure, recorded in Q4 2025.

• On a quarterly basis, Payables rose 115.48% year-over-year to $3.6 million in Q4 2025; TTM through Dec 2025 was $3.6 million, a 115.48% increase from a year earlier, with the FY2025 full-year figure at $3.6 million, up 115.48% from the prior year.
• Payables was $3.6 million for Q4 2025 at Ensysce Biosciences, up from $851160.0 in the prior quarter.
• Over five years, Payables peaked at $13.0 million in Q4 2021 and troughed at $319180.0 in Q1 2021.
• A 5-year average of $3.4 million and a median of $2.0 million in 2023 frame the typical range for Payables.
• Across the five-year window, Payables tumbled 90.87% in 2021 and surged 2103.36% in 2022, its largest moves.
• Over 5 years, Payables stood at $13.0 million in 2021, then plunged by 44.74% to $7.2 million in 2022, then sank by 61.3% to $2.8 million in 2023, then plunged by 40.56% to $1.7 million in 2024, then soared by 115.48% to $3.6 million in 2025.
• The last three Payables figures came in at $3.6 million (Q4 2025), $851160.0 (Q3 2025), and $1.5 million (Q2 2025), per Business Quant data.